Cargando…
Targeting mTOR/p70S6K/glycolysis signaling pathway restores glucocorticoid sensitivity to 4E-BP1 null Burkitt Lymphoma
BACKGROUND: Increasing evidence indicates that rapamycin could be used as a potential glucocorticoid (GC) sensitizer in lymphoblastic malignancies via genetic prevention of 4E-BP1 phosphorylation. Interestingly, we found that combined rapamycin with dexamethasone can effectively reverse GC resistanc...
Autores principales: | Gu, Ling, Xie, Liping, Zuo, Chuan, Ma, Zhigui, Zhang, Yanle, Zhu, Yiping, Gao, Ju |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506760/ https://www.ncbi.nlm.nih.gov/pubmed/26189041 http://dx.doi.org/10.1186/s12885-015-1535-z |
Ejemplares similares
-
Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma
por: Bhatti, Maria, et al.
Publicado: (2018) -
Low dose of 2-deoxy-D-glucose kills acute lymphoblastic leukemia cells and reverses glucocorticoid resistance via N-linked glycosylation inhibition under normoxia
por: Gu, Ling, et al.
Publicado: (2017) -
Targeting mTOR and Glycolysis in HER2-Positive Breast Cancer
por: Holloway, Ryan W., et al.
Publicado: (2021) -
Glycolysis is suppressed by DCZ0801-induced inactivation of the Akt/mTOR pathway in Multiple Myeloma
por: Feng, Qilin, et al.
Publicado: (2020) -
Plasticity and mTOR: Towards Restoration of Impaired Synaptic Plasticity in mTOR-Related Neurogenetic Disorders
por: Gipson, Tanjala T., et al.
Publicado: (2012)